8 programs · prices and safety record checked October 26, 2026
We check who prescribes and who compounds, what the FDA allows, any warning letters, and what you really pay each month. Every fact links to its source.
Ranked by our published score
NAD+ injections or nasal spray from $89 a month on a 12-month plan, evaluation included.
No FDA warning letter foundLowest published plan: NAD+ injection, 12 months, 12-month subscription. Checked 2026-10-26.
Sermorelin or NAD+ reported at about $99 a month, with no membership fee.
No FDA warning letter foundLowest published plan: Sermorelin (entry price), monthly; plan length not published. Checked 2026-10-26.
Peptides inside a lab-led membership: glutathione, NAD+ and sermorelin, plus the membership fee.
No FDA warning letter foundLowest published plan: Basic membership + glutathione, monthly. Checked 2026-10-26.
Sermorelin, NAD+ and glutathione in all 50 states, with a discounted first month.
No FDA warning letter foundLowest published plan: NAD+ injection, monthly after a $89 first month. Checked 2026-10-26.
By treatment
Signals your pituitary to release more of your own growth hormone. Usually a nightly injection.
A coenzyme sold as injections, nasal spray or oral drops; evidence in people is early.
An antioxidant given by injection; often bundled in longevity programs.
A copper peptide used topically for skin and scalp.
Cheapest first
Before you pay
Every program here uses a licensed clinician and a licensed US pharmacy. Vials sold 'for research only' skip both, and nothing about their contents is checked. We don't list them.
FDA decides which bulk substances pharmacies may compound. NAD+ and glutathione are in its 'under evaluation' group, which in practice allows them; BPC-157 is not on the list despite heavy marketing.
The cheapest monthly rates come with 6- or 12-month plans, and most programs refund nothing once the order is placed. Compare the month-to-month price before you commit.
Some programs bill every 4 weeks instead of monthly, which adds a 13th payment each year. We convert those prices to a true monthly figure.
Few programs name their pharmacy or say whether it is a 503A or 503B facility. We note it where they do, and flag it where they don't.
For sermorelin, NAD+ and most longevity peptides, human studies are small. Treat claims about energy, aging or fat loss as unproven until larger trials say otherwise.
Pharmacies may compound only substances FDA allows under section 503A. In 2026 FDA moved several popular peptides off its 'significant safety risks' list because their nominations were withdrawn, which does not make them compoundable, and an advisory committee voted on six of them in July 2026 with no final decision yet.
Three questions. No email needed. We match you on treatment, budget and what is included, then show the top three.
Before a program is listed we search FDA warning letters, note whether it dispenses FDA-approved or compounded drugs, and say who prescribes. What we find goes on its review.
Every price comes from the program's own pricing page, with the link and the date we checked it.
Labs, membership and consult fees are folded in, so the monthly number is what leaves your account.
Each score is computed from five published criteria. What a program pays us changes nothing; bmiMD scores 8.7 on the same scale as everyone else.
Online sermorelin prices hinge on plan length, billing cycle and fees. We compare each program's published plans, what they include and what you can get back.
Sermorelin was FDA-approved as Geref, then discontinued. Here is what FDA said in 2013, why pharmacies compound it, and what the small human studies show.
Prices vary with the plan length: month-to-month plans cost noticeably more than 6- or 12-month prepaid ones. Our price table shows each program's lowest published plan and links to its source.
Sermorelin was FDA-approved as Geref; the maker stopped selling it in 2008 and the approval was withdrawn in 2009, and a 2013 Federal Register notice says that was not for safety or effectiveness reasons. Pharmacies compound it today on a clinician's prescription.
No. Compounded peptides are mixed by a pharmacy for an individual prescription and are not FDA-approved products. FDA keeps lists of which bulk substances pharmacies may use; we note each peptide's status.
BPC-157 is not on FDA's list of substances pharmacies may compound. An FDA advisory committee voted on it in July 2026, but no final decision has been published. None of the programs here sells it today; one runs a waitlist.